Latest EASL-EASD-EASO [1] and AASLD [99] clinical practice guidelines support the use of pioglitazone, a selective PPARγ agonist, in progressive and/or high-risk, biopsy-proven NASH, due to its efficacy regarding liver histology in NASH patients with or without T2DM. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.